Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma

Attallah, Abdelfattah M.; Tabll, Ashraf A.; Elsadany, Mohamed; Ibrahim, Tallat; El-Dosoky, Ibrahim

doi:10.1007/s10238-003-0023-y

Cited by 13 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response of the human immune system against tumors mainly depends on cellular immunity (27). CD3 + T cells are mature T cells, while CD4 + T cells are considered to have a predefined role as Th cells (28). It has been demonstrated that cytotoxicity against tumors is dependent on an appropriate interaction between CD4 + and CD8 + T cells (29).…”

Section: Discussionmentioning

confidence: 99%

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer (CIK) cells have been used as adoptive immunotherapy in cancer. The present study evaluated the effect of CIK cells on immune function in patients with lung cancer. Patients were divided into three groups, according to the treatment received prior to CIK cell treatment: CIK group (no prior treatment), Che-Sur group (prior chemotherapy and surgery) and Che-Rad group (prior chemotherapy and radiotherapy). Following treatment, the average percentage of cluster of differentiation (CD)3 + CD4 + , CD3 + , natural killer (NK) and NKT cells in peripheral blood was significantly higher than that prior to CIK treatment in the Che-Sur and CIK groups, and the levels of interferon-γ in serum were significantly higher than those prior to CIK treatment in the Che-Sur and CIK groups. On the contrary, the levels of interleukin-10 had decreased in these groups following CIK treatment. Subsequently, patients were divided into three groups according to the percentage of CD3 + CD56 + CIK cells that were administered to the patients. The number of NK and NKT cells increased with increasing number of CD3 + CD56 + cells. The patients in the CIK and Che-Sur groups were the most benefited ones following CIK treatment, contrarily to those in the Che-Rad group, since the increase in the number of CD3 + CD56 + CIK cells in the aforementioned patients enhanced the number of NK cells, which exhibit antitumor activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that cytotoxicity against tumor is dependent on an appropriate CD4 + and CD8 + T cell interaction. The ratios of T lymphocyte subsets in peripheral blood are usually disordered in tumor patients [37,38]. The analysis showed the percentage of CD3 + , CD4 + and CD3 + CD4 + T cells significantly increased in the CIK group, compared with the non-CIK group, but the percentage of CD8 + and CD3 + CD8 + T cells significantly decreased in the CIK group, compared with non-CIK group ( p < 0.001).…”

Section: Discussionmentioning

confidence: 99%

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

Tang

et al. 2012

Exp Hematol Oncol

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma.Materials and methodsRandomized phase II and III trials on CIK cell-based therapy were identified by electronic searches using a combination of "hepatocellular carcinoma" and "cytokine-induced killer cells".ResultsThe analysis showed significant survival benefit (one-year survival, p < 0.001; two-year survival, p < 0.001; median overall survival, p < 0.001) in favor of CIK-based therapy. Comparison of CIK group versus non-CIK group resulted in a significantly prolonged progression-free survival (PFS) (p < 0.01). A favored disease control rate (DCR) and overall response rate (ORR) were also observed in patients receiving CIK cell therapy (p < 0.01). Meanwhile, patients in the CIK group showed better quality of life (QoL), diminished HBV-DNA content and AFP level (p < 0.01). Comparing T-lymphocyte subsets in peripheral blood, the analysis showed the ratio of CD3+, CD4+, CD4+CD8+ and CD3+CD4+ T cells significantly increased in the CIK group, compared with the non-CIK group (p < 0.01).ConclusionsCIK cell therapy demonstrated a significant superiority in prolonging the median overall survival, PFS, DCR, ORR and QoL of HCC patients. These results support further larger scale randomized controlled trials for HCC patients with or without the combination of other therapeutic methods.

show abstract

“…In addition to helper T cells, the role of cytotoxic CD8 + Tcells during HCC disease has been evaluated in many studies, where they were attributed a significant role in the killing of tumor cells. In one study, it was reported that there was a significant decrease in CD4 + Tcells in patients with liver cirrhosis and HCC, indicating their importance in facilitating malignancy among cirrhotic patients [34] . They likewise noticed a decreased ratio of helper T cells/suppressive T cells in the peripheral blood of patients with liver cirrhosis and HCC.…”

Section: T Lymphocytesmentioning

confidence: 99%

Immunology of hepatocellular carcinoma

Sachdeva

Chawla

Arora

2015

WJH

103

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is primarily a malignancy of the liver, advancing from a damaged, cirrhotic liver to HCC. Globally, HCC is the sixth most prevalent cancer and the third-most prevalent reason for neoplastic disease-related deaths. A diverse array of infiltrating immunocytes regulates the development and progression of HCC, as is the case in many other cancers. An understanding of the various immune components during HCC becomes necessary so that novel therapeutic strategies can be designed to combat the disease. A dysregulated immune system (including changes in the number and/or function of immune cells, cytokine levels, and the expression of inhibitory receptors or their ligands) plays a key role in the development of HCC. Alterations in either the innate or adaptive arm of the immune system and cross-talk between them make the immune system tolerant to tumors, leading to disease progression. In this review, we have discussed the status and roles of various immune effector cells (e.g. , dendritic cells, natural killer cells, macrophages, and T cells), their cytokine profile, and the chemokine-receptor axis in promoting or impeding HCC.

show abstract

Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma

Cited by 13 publications

References 18 publications

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

Immunology of hepatocellular carcinoma

Contact Info

Product

Resources

About